# LINGYIMED

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/lingyimed

- Industry: Biotechnology
- Headquarters: Shanghai, China
- Website: www.lingyimed.com/
- Total disclosed funding: $14M
- Latest round: Series A (May 6, 2023)
- Investors on record: 5

## About

Based in Shanghai, China, and established in 2021, Lingyi Biotech Co., Ltd., trading as LINGYIMED, is a biotechnology company that focuses on the metabolic, CNS, ophthalmology, and other disease fields, that was established by Dr. Qing Lin and Dr. Yixiong Chen, who are from WuXi AppTec that is a new drug research and development company. Also, Lingyi Biotechnology has been successful in 30 rare disease projects. In December 2025, LINGYIMED raised a venture funding from returning investor Efung Capital and new investor Zhejiang Guangfu United Holding Co., Ltd.

The company focuses on the gene therapy field. It has developed a technology platform, including a rare disease model, Aav carrier development, and a production process platform. Specific product lines include Inherited Metabolic Disorders (IMDS), neurodegenerative diseases, and inherited retinal diseases (IRDS).  

The company’s revenue is generated by providing rare disease animal model functional validation platform and gene therapy.

## Funding rounds

- Series A, May 6, 2023, $14M — Efung Capital, HSG, Huafang Capital, Transfar Group, HJ-Investment

## Investors

- Efung Capital (https://capitalatlas.ai/funds/efung-capital) — Series A
- HSG (https://capitalatlas.ai/funds/hsg) — Series A
- Huafang Capital (https://capitalatlas.ai/funds/huafang-capital) — Series A
- Transfar Group — Series A
- HJ-Investment — Series A